08:30 – 10:05 Session V |
08:30 |
E. O’Neill |
Back-to-basics II: Introduction in radiobiology | Edward O’Neill |
09:15 |
C. Müller |
OP16 Can We Profit from the Auger Electron Emission of Terbium-161 Using Somatostatin Receptor Antagonists? |
09:27 |
D. Niculae |
OP17 Comparative study on 64Cu production on variable energy cyclotrons TR-19 (ACSI) /KIUBE (IBA) using solid and liquid targets |
09:39 |
F. Barbaro |
OP18 natCr(p,x) or natV(α,x)? Dosimetric assessments at comparison for high-purity 52gMn PET tracer production |
09:51 |
U.A. Kvitastein |
OP19 Production and Separation of the PET-radionuclide Ti-45 from a Liquid nat-Sc Target for Ligand Complexation |
10:15 – Meet the Author poster session with coffee break
10:35 – 12:20 Session VI |
10:35 |
R. Eychenne |
Invited Lecture 4: Alpha particle therapy – are we there yet |
11:20 |
M. Spahn |
OP20 Second generation Al18F-labeled D-amino acid based peptide for CXCR4 targeted molecular imaging |
11:32 |
T. S. Zavvar |
OP21 Preclinical testing and automated synthesis of [177Lu]-labelled DOTA-MGS5 for application in CCK2R-targeted therapy |
11:44 |
K. Lu |
OP22 Synthesis and evaluation of two 18F-labeled Lys-ureido-Aad derivatives for imaging prostate-specific membrane antigen expression with positron emission tomography |
11:56 |
F. Krutzek |
OP23 Synthesis and Biological Evaluation of Chelator-Based Small Molecule PET-Radiotracers for Imaging of PD-L1 |
12:08 |
S. Pandey |
OP24 Affinity of 68Ga-DOTAGA-IAC towards αvβ3 integrin receptor and application in imaging tumor angiogenesis |
12:20 – Lunch
13:45 – 15:18 Session VII |
13:45 |
C. Groot |
Invited Lecture 5: Tau PET imaging: the clinical challenges |
14:30 |
C. Vaccarin |
OP25 Development of ACE-selective radioligands as molecular tools to investigate the imbalance of the renin-angiotensin-aldosterone system during Covid-19. |
14:42 |
L. Meléndez-Alafort |
OP26 Comparison of preclinical dosimetric studies of 177Lu-scFvD2B, 177Lu-PSMA-617 and 177Lu-iPSMA |
14:54 |
N. Lepareur |
OP27 Preliminary results of the Lip-Re1 phase 1 trial: pharmacokinetics study of 188Re-SSS/Lipiodol for HCC treatment |
15:06 |
J. Pougoue Ketchemen |
OP28 Theranostic potential of [67Cu]Cu-NOTA-trastuzumab against HER2 positive breast cancer. |
15:18 – Coffee Break / Poster Viewing Session
16:30 – 17:30 Session VIII |
16:30 |
|
Debate: GMP, The Italian vs Austrian approach | Clemens Decristoforo, Marianne Patt, Petra Kolenc-Peitl, Sergio Todde |
17:00 |
T. Kroon, E. Pel |
Pharmacopoeia Corner, |